vs
Side-by-side financial comparison of OLD SECOND BANCORP INC (OSBC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $93.8M, roughly 1.9× OLD SECOND BANCORP INC). OLD SECOND BANCORP INC runs the higher net margin — 27.3% vs 1.6%, a 25.6% gap on every dollar of revenue. Over the past eight quarters, OLD SECOND BANCORP INC's revenue compounded faster (15.1% CAGR vs -0.2%).
U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
OSBC vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $93.8M | $177.4M |
| Net Profit | $25.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 27.3% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | 159.2% | — |
| EPS (diluted) | $0.48 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $93.8M | $177.4M | ||
| Q4 25 | $95.2M | $196.9M | ||
| Q3 25 | $95.9M | $179.5M | ||
| Q2 25 | $75.1M | $181.1M | ||
| Q1 25 | $73.1M | $168.9M | ||
| Q4 24 | $73.2M | $187.3M | ||
| Q3 24 | $71.2M | $168.6M | ||
| Q2 24 | $70.8M | $178.0M |
| Q1 26 | $25.6M | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $9.9M | $5.4M | ||
| Q2 25 | $21.8M | $-4.8M | ||
| Q1 25 | $19.8M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $23.0M | $-143.5M | ||
| Q2 24 | $21.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 41.2% | 1.2% | ||
| Q3 25 | 13.6% | 3.5% | ||
| Q2 25 | 38.9% | 4.7% | ||
| Q1 25 | 35.8% | 1.2% | ||
| Q4 24 | 34.7% | 13.2% | ||
| Q3 24 | 41.9% | -82.8% | ||
| Q2 24 | 41.2% | 15.9% |
| Q1 26 | 27.3% | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 10.3% | 3.0% | ||
| Q2 25 | 29.0% | -2.7% | ||
| Q1 25 | 27.1% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 32.3% | -85.1% | ||
| Q2 24 | 30.9% | 10.6% |
| Q1 26 | $0.48 | $0.07 | ||
| Q4 25 | $0.53 | $0.05 | ||
| Q3 25 | $0.18 | $0.12 | ||
| Q2 25 | $0.48 | $-0.11 | ||
| Q1 25 | $0.43 | $0.10 | ||
| Q4 24 | $0.42 | $0.38 | ||
| Q3 24 | $0.50 | $-3.11 | ||
| Q2 24 | $0.48 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $115.7M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $893.3M | $653.9M |
| Total Assets | $6.8B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $115.7M | $144.3M | ||
| Q4 25 | $124.0M | $238.4M | ||
| Q3 25 | $116.5M | $246.3M | ||
| Q2 25 | $141.8M | $445.9M | ||
| Q1 25 | $256.1M | $493.6M | ||
| Q4 24 | $99.3M | $484.6M | ||
| Q3 24 | $115.8M | $453.8M | ||
| Q2 24 | $120.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $893.3M | $653.9M | ||
| Q4 25 | $896.8M | $693.1M | ||
| Q3 25 | $866.7M | $727.2M | ||
| Q2 25 | $718.6M | $757.8M | ||
| Q1 25 | $694.5M | $798.5M | ||
| Q4 24 | $671.0M | $778.3M | ||
| Q3 24 | $661.4M | $749.6M | ||
| Q2 24 | $619.3M | $879.3M |
| Q1 26 | $6.8B | $1.2B | ||
| Q4 25 | $6.9B | $1.3B | ||
| Q3 25 | $7.0B | $1.3B | ||
| Q2 25 | $5.7B | $1.5B | ||
| Q1 25 | $5.7B | $1.6B | ||
| Q4 24 | $5.6B | $1.6B | ||
| Q3 24 | $5.7B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
